HBIO 📈 Harvard Bioscience - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4169061052
HBIO: Pumps, Instruments, Analyzers, Measuring, Implantable, Systems, Solutions
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts. Web URL: https://www.harvardbioscience.com
Additional Sources for HBIO Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HBIO Stock Overview
Market Cap in USD | 93m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2000-12-07 |
HBIO Stock Ratings
Growth 5y | -34.8% |
Fundamental | -44.3% |
Dividend | - |
Rel. Strength Industry | -1223 |
Analysts | 5/5 |
Fair Price Momentum | 1.68 USD |
Fair Price DCF | 0.36 USD |
HBIO Dividends
No Dividends PaidHBIO Growth Ratios
Growth Correlation 3m | -81.5% |
Growth Correlation 12m | -96.2% |
Growth Correlation 5y | -11.7% |
CAGR 5y | -5.89% |
CAGR/Mean DD 5y | -0.16 |
Sharpe Ratio 12m | -1.33 |
Alpha | -96.68 |
Beta | 1.45 |
Volatility | 61.83% |
Current Volume | 322.3k |
Average Volume 20d | 175.7k |
What is the price of HBIO stocks?
As of December 21, 2024, the stock is trading at USD 2.11 with a total of 322,349 shares traded.
Over the past week, the price has changed by -2.31%, over one month by -2.31%, over three months by -23.27% and over the past year by -57.80%.
As of December 21, 2024, the stock is trading at USD 2.11 with a total of 322,349 shares traded.
Over the past week, the price has changed by -2.31%, over one month by -2.31%, over three months by -23.27% and over the past year by -57.80%.
Is Harvard Bioscience a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Harvard Bioscience (NASDAQ:HBIO) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.32 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HBIO as of December 2024 is 1.68. This means that HBIO is currently overvalued and has a potential downside of -20.38%.
Probably not. Based on ValueRay Fundamental Analyses, Harvard Bioscience (NASDAQ:HBIO) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.32 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HBIO as of December 2024 is 1.68. This means that HBIO is currently overvalued and has a potential downside of -20.38%.
Is HBIO a buy, sell or hold?
Harvard Bioscience has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy HBIO.
Harvard Bioscience has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy HBIO.
- Strong Buy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for HBIO stock price target?
According to ValueRays Forecast Model, HBIO Harvard Bioscience will be worth about 1.9 in December 2025. The stock is currently trading at 2.11. This means that the stock has a potential downside of -11.85%.
According to ValueRays Forecast Model, HBIO Harvard Bioscience will be worth about 1.9 in December 2025. The stock is currently trading at 2.11. This means that the stock has a potential downside of -11.85%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6.3 | 196.2% |
Analysts Target Price | 6.4 | 204.3% |
ValueRay Target Price | 1.9 | -11.8% |